

P&amp;E Draft for 10173-073-999 - Monday, August 4, 2003

**IN THE CLAIMS:**

Applicant's note that the Examiner has renumbered previously cancelled claims 1-4 and 9-20 as claims 1-16 and renumbered claims 21-47 as claims 17-43. Please cancel claims 30-43 without prejudice to Applicant's right to pursue the subject matter of the canceled claims in one or more continuation, continuation-in-part, or divisional applications. Please amend claims 17-29 as indicated below. In compliance with proposed 37 C.F.R. § 1.121, a complete listing of the claims is presented below. For currently amended claims deleted language is shown by strikethrough and added language is shown by underlining. No new matter has been added.

Claims 1-16 (cancelled)

17. (currently amended) A method for treating a vascular disease or condition selected from the group consisting of atherosclerosis, hyperlipidemia and hypoalphalipoproteinemia in a human, comprising administering to a human in need thereof a pharmaceutically acceptable and a therapeutically effective amount of empty unilamellar phospholipid liposomes wherein at least about 68% of the liposomes have a mean diameter of  $125 \pm 30$  nm.

18. (currently amended) ~~The method of claim 21 wherein at least about 68% of the liposomes have a mean diameter between 100-150 nm~~ A method for treating a vascular disease or condition selected from the group consisting of atherosclerosis, hyperlipidemia and hypoalphalipoproteinemia in a human, comprising administering to a human in need thereof a pharmaceutically acceptable and a therapeutically effective amount of empty unilamellar phospholipid liposomes wherein at least about 68% of the liposomes have a mean diameter of 100-150 nm.

19. (currently amended) The method of claim ~~21~~17 or 18 wherein the liposomes are free of drug.

20. (currently amended) The method of claim ~~21~~17 or 18 in which the therapeutically effective amount is in the range of about 10 mg to about 1600 mg per kg body weight.

21. (currently amended) The method of claim ~~21~~17 or 18 in which the therapeutically effective amount is about 300 mg per kg body weight.

22. (currently amended) The method of claim ~~21~~17 or 18 in which the therapeutically effective amount is about 0.1-1.5 gm/kg.

23. (currently amended) The method of claim ~~21~~17 or 18 in which the therapeutically effective amount is about 0.28-0.42 gm/kg.

P&E Draft for 10173-073-999 - Monday, August 4, 2003

24. (currently amended) The method of claim ~~21~~17 or 18 in which the liposomes are administered once.

25. (currently amended) The method of claim ~~21~~17 or 18 in which the liposomes are administered more than once.

26. (currently amended) The method of claim ~~21~~17 or 18 in which the liposomes are administered in repeated doses.

27. (currently amended) The method of claim ~~21~~17 or 18 in which said liposomes are administered weekly.

28. (currently amended) The method of claim ~~21~~17 or 18 in which said liposomes are administered one dose per week for 4 to 16 weeks.

29. (currently amended) The method of claim ~~21~~17 or 18 in which said liposomes are administered one dose per week for 10 weeks.

Claims 30-43 (cancelled)